Intramuscular and intravenous levetiracetam in humans: safety and pharmacokinetics.
A study in dogs demonstrated that the commercially available formulation of IV levetiracetam (LEV) could be given safely IM and was quickly and completely absorbed. In this crossover study, 5 women and 5 men were given IM and IV LEV. This study demonstrates that administration of 5ml (500mg) IM LEV is well tolerated and its bioavailability is equivalent to an IV injection.
Leppik
Ilo E
IE
University of Minnesota, Minneapolis, MN 55455, United States; MINCEP Epilepsy Care, Minneapolis, MN 55416, United States. leppi001@umn.edu
Goel
Varun
V
Rarick
John
J
Nixdorf
Donald R
DR
Cloyd
James C
JC
D000328:Adult; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D000077287:Levetiracetam; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement / Q000379:methods; D010889:Piracetam / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D055815:Young Adult
D000077287:Levetiracetam; D010889:Piracetam